Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2637438 | 0.98 | LTA4H (0.33) | LTA4HCRBNCHRM2CHRM3GRIN1 | |
| Hydrochloric Acid SCHEMBL2637436 | 0.96 | OTUD7B (0.34) | LTA4HCRBNCHRM2CHRM3GRIN1 | |
| SCHEMBL24717655 | 0.88 | CRBN (0.43) | LTA4HCRBNCHRM2CHRM3GRIN1 | |
| SCHEMBL7715274 | 0.88 | HRH3 (0.38) | LTA4HCRBNGRIN1GRIN2AHRH3 | |
| SCHEMBL24782527 | 0.84 | — | — | |
| SCHEMBL1753723 | 0.83 | NEK2 (0.38) | CRBNPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20474682 | 0.81 | CHRM2 (0.34) | LTA4HCRBNCHRM2CHRM3GRIN1 | |
| SCHEMBL3436929 | 0.80 | CHRM2 (0.48) | LTA4HCHRM2CHRM3GRIN1GRIN2A | |
| SCHEMBL25738952 | 0.80 | GRIN1 (0.40) | LTA4HCRBNCHRM2CHRM3GRIN1 | |
| SCHEMBL13460109 | 0.80 | GRIN1 (0.40) | LTA4HCRBNCHRM2CHRM3GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747234-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | claimed |
| WO-2025017103-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | claimed |
| US-7273865-B2 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1670805-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | claimed |
| WO-2005028484-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | claimed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | claimed |
| EP-4747234-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025017103-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | disclosed |
| US-20240382475-A1 | Quinazoline Derivative, Or Preparation Method Therefor And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-117940411-A | Quinazoline derivative, or preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | disclosed |
| CN-1871244-A | Thiazolopyridine derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2006-11-29 | — | — | CN | disclosed |
| EP-1670805-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670805-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005028484-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005028484-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382475-A1 | Quinazoline Derivative, Or Preparation Method Therefor And Use Thereof | SOS1, WEE1, SLC5A1 | LTA4H 2661/4885CRBN 3557/4885CHRM2 4520/4885 |
| US-20050065151-A1 | Thiazolopyridine | ADORA2A, ADORA3, ADORA1 | LTA4H 1549/4885CRBN 3433/4885CHRM2 49/4885 |
| US-20070129345-A1 | Lactam compounds and methods of using the same | HSD11B1, HSD17B11, HSD17B1 | LTA4H 329/4885CRBN 2523/4885CHRM2 4781/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | LTA4H 4121/4885CRBN 1041/4885CHRM2 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.